This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
It appears that the analysis of the clinical study was conducted on an intention to treat basis. The primary health outcome used was the frequency of atrial fibrillation. The secondary health outcomes were: beta-blocker tolerance, the frequency of stroke, the frequency of ventricular tachycardia, the occurrence rates of adverse effects (bradycardia, heart block, nausea and hypotension), the levels of thyroid-stimulating hormone and aminotransferase, and the length of stay.
The baseline characteristics of the groups were generally similar except for a higher percentage of patients who had experienced a myocardial infarction in the amiodarone group, (p=0.005). The surgical characteristics were also generally similar. The exceptions were fewer patients in the amiodarone group required defibrillation to restore sinus rhythm after aortic cross-clamp release, (p=0.04) and the pump heart rate pre-and post cardiopulmonary bypass.
Effectiveness results
The overall risk of atrial fibrillation was reduced by 41% with amiodarone (frequency with amiodarone 23% versus 38% with placebo; p=0.01).
Postoperative beta-blockers were tolerated in a similar percentage of patients in the amiodarone and placebo groups (70% versus 64%; p=0(758).
Amiodarone was more beneficial in the following sub-groups: patients with no tolerance to preoperative beta-blockers, those with normal left atrial size, those with no history of atrial fibrillation or heart failure, and those older than 70 years.
Amiodarone significantly lowered the frequency of cerebrovascular accident and ventricular tachycardia (frequency with amiodarone 2% versus 7% with placebo; p=0.04 for each).
The occurrence rates of adverse effects were similar in the two groups, although there was a trend toward more nausea with amiodarone (27% versus 16%; p=0.056).
Cost results
The costs in all departments were similar between the amiodarone and placebo groups, (p>0.05 for all comparisons).
The mean total cost was $15,565 (+/-9,832) in the amiodarone group versus $16,126 (+/-8,043) in the placebo group (difference $561/patient; p=0.12).
In the one-way sensitivity analysis, the findings remained robust to changes in the effectiveness and cost of amiodarone.
Synthesis of costs and benefits
A synthesis of the cost and effectiveness data was not relevant since amiodarone was the dominant strategy (the costs between the amiodarone and placebo groups were similar, but amiodarone was more effective than placebo).
Authors' conclusions
Routine prophylaxis with amiodarone in addition to standard care with beta-blockers is cost-effective, compared with standard care alone, in patients undergoing open heart surgery.
CRD COMMENTARY -Selection of comparators
The choice of the comparator (beta-blockers alone) was justified as it represented the standard prophylaxis to prevent postoperative fibrillation in patients undergoing open heart surgery. The authors mentioned other possible interventions that were not included in the analysis. You should decide whether the comparator used represents a valid comparator in your own setting.
Validity of estimate of measure of effectiveness
A prospective double-blinded randomised study was performed, which was appropriate for the study question. Power calculations were carried out and these justified the size of the sample used in the study. The study groups were comparable at baseline, thus confounding factors are probably low. The investigators were blinded to the allocation of patients to the study groups; therefore, few assessment biases may have occurred. The data came from a single centre and this may hinder the generalisability of the results to other settings. Relevant statistical analyses were undertaken to compare health outcomes between the groups.
Validity of estimate of measure of benefit
No summary benefit measure was used in the analysis so, in effect, a cost-consequences analysis was carried out. Please refer to the comments in the 'Validity of estimate of measure of effectiveness' field (above).
Validity of estimate of costs
The perspective of the study (hospital) was stated. It appears that all the relevant categories of costs have been included in the analysis. The professional fees were omitted from the analysis since physicians and surgeons were not employed by the hospital. No justification was provided for the exclusion of costs after the initial hospitalisation. Since there was a significant reduction in the frequency of stroke, these costs might have differed between the two groups and, therefore, the omission might have biased the results in favour of the placebo group.
Details on the unit costs and resource quantities were not reported, which limits the transferability of the economic analysis to other settings. The authors acknowledged that the costs incurred might have been protocol driven and these trials have low external validity. The authors reported a cost-to-charge ratio mechanism to derive costs which is methodologically superior to the reporting of charges only. Discounting was not carried out as the costs were incurred during less than 2 years. Statistical tests of the costs were performed when the cost estimates were compared. Sensitivity analyses were performed on the costs to test the robustness of the results.
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